Compound 2 was able tostrongly inhibit the growthof leukemia, melanoma and breast cancer cell lines in the NCI-60 antiproliferationscreen (Table S3), in agreement with the published anti-proliferative effects ofCBP/EP300-BRD inhibitors in leukemia lines.,, It was, thus, not surprising to observea reduction in THP-1 cell proliferation following a 3 day treatmentwith all of our tested compounds (Figure e), likely due, at least in part, to theireffects on myc expression (Figure e,g). This evidence concerns the gene MYC and breast carcinoma.